While various treatment approaches similar to cutaneous melanoma have been evaluated, such as systemic chemotherapy, immunotherapy with immune checkpoint inhibitors targeting the T-lymphocyte-associated antigen 4 (CTLA-4) (ipilimumab, tremelimumab) [11] or programmed cell death-1 (PD-1) (nivolumab, pembrolizumab), and targeting of the soluble T cell receptor (TCR) with IMCgp100, unfortunately UM does not respond as well as cutaneous melanoma to treatment and no consensus has yet been reached for its care, with prevention of metastatic disease remaining the most effective option [11]. The gene discussed is CTLA4; the disease is cutaneous melanoma.